February 1, 2017 05:13 PM EST
R&D

Avi­ra­gen shares plunge as RSV an­tivi­ral flunks a small PhI­Ia study

John Carroll

Editor & Founder

The an­tivi­ral biotech Avi­ra­gen $AVIR says that its ex­per­i­men­tal RSV ther­a­py BTA585 flunked a small Phase IIa study in vol­un­teers who had been in­tranasal­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times